Skip to content
Search

Latest Stories

GPhC updates guidance on weight loss medicines; CCA says ‘no need for additional regulation’

GPhC introduces additional safeguards for online supply of weight loss medicines
GPhC introduces additional safeguards for online supply of weight loss medicines

CCA argues that current regulations and guidance, when followed, are sufficient for the safe online supply of weight loss medicines

Addressing the concerns regarding online prescribing and supply of weight loss medicines, the General Pharmaceutical Council (GPhC) has confirmed that an updated guidance will be issued soon.

In a statement released on Tuesday (28 Jan), Louise Edwards, GPhC's chief strategy officer, highlighted that the revised guidance will introduce additional safeguards for high-risk medicines, including those used for weight management.


"We require all pharmacies, including those operating online, to ensure that the way in which pharmacy services are delivered safeguards the health, safety and wellbeing of patients and the public,” Edwards said.

He emphasised that their current guidance was specifically designed to ensure the safe and effective provision of pharmacy services at a distance, which online pharmacies in Great Britain were expected to follow.

It requires that prescribers adhere to national prescribing guidelines for the UK and follow good practice guidance.

Regarding the updated guidance, Edwards said: "We are issuing an updated version of our guidance for supplying medicines at a distance, including on the internet, shortly, which will set out additional safeguards around high-risk medicines, including medicines used for weight management.”

NPA demands tougher regulation 

The GPhC ran a consultation on the revised guidance from 17 September to  9 October 2024, inviting feedback from the public, carers, pharmacists, pharmacy technicians, other healthcare professionals, and pharmacy owners.

In its response, the National Pharmacy Association (NPA) stated that proposed safeguards “still leaves the door open for medicines to be prescribed/supplied without appropriate patient consultation and access to patient records.”

The association, representing independent community pharmacies, urged the regulator to mandate a full two-way consultation with patients and a thorough review of their medical history before dispensing ‘higher risk’ medication such as weight loss jabs.

No additional regulation required – CCA

However, the Company Chemists’ Association (CCA) disagreed with the need for additional regulation on the online sale of weight loss medicines.

CCA’s chief executive Malcolm Harrison said“CCA members have been remotely providing weight loss medicines to patients for many years with a proven track record of safety.

“When current regulation and guidance are followed, the prescribing and supply of these medicines is safe and meets a clear patient need.

 “We do not see the need for any additional regulation,” he added.

A CCA spokesperson emphasised the importance of adhering to current regulations and guidance by all online suppliers before considering further regulation and guidance.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less